- Home
- JANX
as 12-20-2024 4:00pm EST
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.6B | IPO Year: | 2021 |
| Target Price: | $83.09 | AVG Volume (30 days): | 1.7M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.19 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.79 - $71.71 | Next Earning Date: | 11-06-2024 |
| Revenue: | $13,049,000 | Revenue Growth: | 54.12% |
| Revenue Growth (this year): | 40.27% | Revenue Growth (next year): | -69.84% |
Stock Insider Trading Activity of Janux Therapeutics Inc. (JANX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell David Alan | JANX | President and CEO | Dec 3 '24 | Sell | $67.00 | 15,000 | $1,005,000.00 | 242,054 | |
| Campbell David Alan | JANX | President and CEO | Nov 25 '24 | Sell | $51.74 | 25,000 | $1,289,878.73 | 242,054 | |
| Campbell David Alan | JANX | President and CEO | Oct 28 '24 | Sell | $53.58 | 25,000 | $1,338,558.90 | 242,054 | |
| RA CAPITAL MANAGEMENT, L.P. | JANX | Director10% Owner | Oct 18 '24 | Buy | $44.75 | 1,200,000 | $53,700,000.00 | 9,317,246 | |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Oct 16 '24 | Sell | $49.44 | 1,673,128 | $77,472,371.23 | 6,445 | |
| DiRaimondo Thomas | JANX | Chief Scientific Officer | Sep 27 '24 | Sell | $46.72 | 5,000 | $231,716.19 | 98,613 | |
| Meyer Andrew Hollman | JANX | Chief Business Officer | Sep 27 '24 | Sell | $45.96 | 50,000 | $2,297,755.00 | 67,592 | |
| Campbell David Alan | JANX | President and CEO | Sep 27 '24 | Sell | $46.93 | 25,000 | $1,157,641.43 | 242,054 | |
| Avalon Ventures XI, L.P. | JANX | 10% Owner | Sep 26 '24 | Sell | $47.04 | 307,779 | $14,452,393.76 | 6,445 |
Latest Janux Therapeutics Inc. News
JANX Breaking Stock News: Dive into JANX Ticker-Specific Updates for Smart Investing
Business Wire
16 days ago
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
MT Newswires
17 days ago
Janux Therapeutics Prices $350 Million Offering of Shares, Warrants
Business Wire
17 days ago
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
Motley Fool
18 days ago
Why Janux Therapeutics Crushed the Market Today
Zacks
18 days ago
JANX Stock Hits Record High on Prostate Cancer Study Data
MT Newswires
19 days ago
Janux Therapeutics Launches $300 Million Offering
Investor's Business Daily
19 days ago
Janux Catapults 49% On 'Unprecedented' Results In Prostate Cancer; Vir Goes For A Ride
Business Wire
19 days ago
Janux Therapeutics Announces Proposed Public Offering
Compare JANX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JANX Janux Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.